###### Key questions

What is already known about this subject?
=========================================

-   Proteomic changes in myocardium have been studied in adult patients with or without ischaemic arrest, and our laboratory has identified genetic changes in the myocardium of children undergoing cardiac surgery.

What does this study add?
=========================

-   To date, this is a unique study that identifies the proteomic differences in right ventricular myocardium from infants undergoing cardiac surgery for cyanotic and acyanotic heart diseases with a hypertensive right ventricle.

How might this impact on clinical practice?
===========================================

-   It is of clinical concern how to manage such children, as to the timing of surgery, the type of inotrope that might benefit the child with each cardiac condition and individual mechanisms that might be accessed in precision medicine to determine the best therapy for each child. This study is the first step in that process to identify the mechanisms involved and the best treatment for the individual child.

Background {#s1}
==========

It is estimated that about 1% of all live-born babies are affected by cardiac congenital malformations. Intracardiac surgical repair in these patients is associated with a low mortality in infants and children (\<5%). More importantly, a growing number of patients survive into adulthood with hypertensive right ventricles (RV). Heart failure due to RV dysfunction is a major cause of morbidity in this population, and a significant proportion of them will die as a result. There is recent evidence that the mortality is increasing in the teenage population who are dying of the complications of cardiac surgery performed over a decade ago, and it is our responsibility to improve this for the next generation.[@R1] The gravity of the problem is well explained by the 2009 WHO annual report that puts the disability-adjusted life-year for congenital heart disease higher than diseases such as diabetes or hypertension.[@R2] At present, pharmacotherapy of heart failure may improve clinical symptoms, but there is no targeted pharmacotherapy to improve RV systolic and diastolic function or to prevent or even reverse the remodelling of the RV. Significant morbidity secondary to RV dysfunction leads to greater length of time on the paediatric intensive care unit (PICU) postoperatively and more expensive repeat interventions and reoperations. Since each day on the PICU can cost up to £2000, and each reoperation costs £25000, it will be beneficial to the healthcare economy to improve the quality of individualised care we deliver to these children.

One drawback in this area is the fact that patients with RV dysfunction are grouped together despite the fact that there are different congenital cardiac disorders that will trigger different functional, molecular and cellular remodelling in the RV. It is therefore vital to dissect potential differences in cell signalling and remodelling in patients with different causes of RV dysfunction. Consequently, a greater understanding of the underlying mechanisms of RV function in different congenital cardiac disorder groups will help to formulate strategies targeting individual cardiac disorders. The National Heart, Lung, and Blood Institute (Bethesda, Maryland, USA) has been awarded top priority to research on pathophysiology of the RV. RV dysfunction is caused by changes in the cell fate and tissue composition. These changes occur due to cell signalling that may be initiated by various factors including oxidative stress and lead to alterations in cell survival, structural (cytoskeletal) and extracellular proteins, protease activity and calcium handling properties.[@R3] From our recent studies, we have shown that chronic hypoxaemia in cyanotic children with tetralogy of Fallot (TOF) induced the expression of genes associated with apoptosis and reduced the expression of genes associated with normal myocyte contractility and function.[@R3]

It is well established that convergence of the signalling pathways activated by tumour growth factor-β, Wnts and cadherin are critical for development and its importance re-emerge in disease. It plays a key role in cell fate (growth and survival) and in matrix synthesis and remodelling, which are all pertinent processes in RV dysfunction. We already have extensive evidence for their important role in blood vessel remodelling and propose that modulation of these signalling pathways contribute to RV dysfunction. Although right ventricular failure (RVF) is the hallmark of pulmonary arterial hypertension (PAH), the mechanism of RVF is unclear. Development of PAH-induced RVF is associated with an increased reactive oxygen species (ROS) production. Increases in oxidative stress lead to generation of nitro-tyrosine residues in tissue inhibitor of metalloproteinase and liberate active matrix metalloproteinase.[@R4]

The purpose of this study is to investigate the cellular signalling changes associated with RV hypertension in the setting of congenital heart disease. This would lead to a better understanding of the determinants of RV function in patients with hypertrophy associated with different congenital cardiac malformations. It was proposed that:Changes in key myocardial cellular signalling pathways triggered by hypertension-induced RV dysfunction in congenital cardiac disorders depend on the type of malformation and systemic oxygen saturation.The pathology-induced cellular and molecular changes will result in differences in postoperative stay within the hospital.Identifying differences in the cellular signalling pathways between those with large septal defects and those with TOF might enable us to tailor therapies for each pathology to improve outcome.

The clinical outcome in our patients often depends on the ability of the RV to cope with the anatomical substrate and the effect of cardiopulmonary bypass. We hoped to be able to understand better the effect of these and hence to modify our treatment accordingly. This might lead to better and perhaps individualised care for our patients undergoing cardiopulmonary bypass for congenital heart diseases.

Patients and methods {#s1a}
--------------------

### Inclusion criteria {#s1a1}

We compared patients with RV hypertension who underwent cardiopulmonary bypass and consented for inclusion between 1 July 2015 and 31 March 2017. We report on two groups of children with right ventricular pressures at systemic level: group 1: pulmonary hypertension due to large septal defects, such as ventricular septal defect (VSD) and group 2: obstructed RV (as in TOF). In group 1, left to right shunt was the cause of RV hypertension. In group 2, the children were cyanosed, and the RV was functioning under a significant obstructive afterload.

### Exclusion criteria {#s1a2}

Children with additional syndromes were excluded (apart from Trisomy 21) due to the unknown effect on ventricular function and protein analysis. Parents who were not able to consider the information at least 1 week before operation were excluded, hence excluding any children undergoing emergency surgery. In addition, we excluded those with sepsis or coexisting morbidity, which might alter the protein analysis.

Fully informed consent was obtained from parents prior to admission for operation. Clinical data were obtained from patient's clinical records and Heartsuite Database at the time of cardiac surgery. Demographic data were recorded, including details of cardiac anatomy and systemic oxygen saturations. At operation, tissue samples were obtained from right ventricular myocardium as soon as possible after instituting cardiopulmonary bypass to minimise the effect of this on protein analysis.

Protein analysis technique is online [supplement](#SP1){ref-type="supplementary-material"}.
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Clinical data {#s1b}
-------------

The patient clinical outcome data that was recorded were standard operative and postoperative data. This included bypass time, cross clamp time, recorded pressure in the superior vena cava at 4 hours postoperative, time in intensive care, time on mechanical ventilation, time of pleural effusion drainage, requirement for postoperative oxygen therapy and time to discharge. In addition, we recorded the requirement for inotropic support both for length of time this was needed but also which inotrope was used.

Tissue studies {#s1c}
--------------

Biopsies were taken from the free wall of the RV of patients with VSD (n=6) or with TOF (n=6) immediately after starting cardiopulmonary bypass. Tissue was either snap frozen in liquid nitrogen or placed in Allprotect tissue reagent (Qiagen, Manchester, UK) before being stored at −80°C.

Echocardiography {#s1d}
----------------

Echocardiography was performed using a Vivid 9 or IE33 echocardiographic machines using standard assessment of preoperative and postoperative characteristics, including cardiac anatomy in addition to function. Left heart function assessment included fractional shortening in long axis view, mitral annular plane systolic excursion (not indexed), mitral E wave/A wave (E/A wave) ratio and volume time integral of left ventricular outflow tract Doppler. Right heart function similarly included tricuspid annular plane systolic excursion (not indexed), fractional area length change and lateral wall tissue Doppler. An assessment was made of diastolic function by Doppler interrogation of inflow velocity through the mitral and tricuspid valve and also the presence or absence of diastolic A wave velocity in the pulmonary artery.

Statistical comparison {#s1e}
----------------------

For the data that were parametric, mean and SD are presented with paired t-test values (P\<0.05 being significant). For the data that were non-parametric, median (range) is presented with Wilcoxon values (P\<0.05 being significant). Significance of proteomic data was determined as described above.

Results {#s2}
=======

Clinical data {#s2a}
-------------

The demographic and clinical data are displayed in [table 1](#T1){ref-type="table"}; children in each group had similar age, sex ratio and weight. On preoperative echocardiogram, all children had systemic level right ventricular pressure, with an unrestrictive VSD. Those with TOF were significantly cyanosed, with severe infundibular pulmonary stenosis. All had good systolic function preoperatively, and there was no difference in bypass time or cross-clamp time at operation.

###### 

Patient demographics, preoperative and intraoperative characteristics

                                    Group 1 VSD   Group 2 TOF   P value
  --------------------------------- ------------- ------------- ---------
  Age (years)                       0.38 (0.13)   0.37 (0.13)   ns
  Weight (kg)                       4.81 (0.41)   5.89 (1.01)   ns
  Oxygen saturations (%)            97.5 (2.6)    82.8 (6.2)    0.0038
  Male:female                       3:3           3:3           ns
  Systolic blood pressure (mm Hg)   83.8 (10.9)   88.5 (13.6)   ns
  Fractional shortening (%)         34.7 (2.5)    34.0 (8.5)    ns
  Bypass time (minutes)             117 (127)     140 (28)      ns
  Cross-clamp time (minutes)        86 (95)       87(51)        ns

Data displayed as mean (SD).

P\<0.05 was significant.

TOF, tetralogy of Fallot; VSD, ventricular septal defect.

Postoperatively, there were some differences in the RV function, as seen in [table 2](#T2){ref-type="table"}. Those from the TOF group having good systolic function and good cardiac output. However, there was evidence of increased stiffness in the RV with a significantly higher tricuspid E/A ratio (VSD group 0.84 (0.3) compared with TOF group 1.95 (0.4) (P=0.009) and high incidence of pulmonary diastolic forward flow (A wave) (0/6 in the VSD group and 5/6 in the TOF group (P=0.001)).

###### 

Echocardiographic assessment postoperatively, comparison of VSD group and TOF group

                              Group 1 VSD   Group 2 TOF   P value
  --------------------------- ------------- ------------- ---------
  Heart rate                  125 (14)      141 (14)      0.044
  Fractional shortening (%)   30.43 (2)     32.5 (4)      ns
  MAPSE (mm)                  7 (1)         6.8 (1)       ns
  Aortic VTI (mL/s)           12.2 (3)      13 (3)        ns
  TAPSE (mm)                  6 (1)         7.43 (2)      ns
  Tricuspid E/A ratio         0.84 (0.3)    1.95 (0.4)    0.009
  Tricuspid S′ (cm/s)         6 (1)         4.7 (1)       ns
  Pulmonary A wave            0/6           5/6           0.001

Data displayed as mean (SD).

P\<0.05 is significant.

E/A ratio, E wave/A wave ratio; MAPSE, mitral annular plane systolic excursion; S′, tissue Doppler assessment of free wall movement; TAPSE, tricuspid annular plane systolic excursion; TOF, tetralogy of Fallot; VSD, ventricular septal defect; VTI, velocity time integral.

Proteomics analysis {#s2b}
-------------------

A total of 3610 protein accession numbers (representing 3342 gene names; note that this number differs in [table 3](#T3){ref-type="table"} (2357 gene names) due to the PantherDB database version used) were identified that were found in RV samples from both heart pathologies and that fulfilled all criteria outlined above. Of these, 200 were found to significantly change (±1.3-fold, P\<0.05) between pathologies: 26 were lower in TOF samples and 174 were higher in TOF ([figure 1](#F1){ref-type="fig"}). Gene ontology analysis was performed using these proteins found in both TOF and VSD samples and which significantly changed or not ([table 4](#T4){ref-type="table"}).

###### 

Number of proteins in proteomics analysis, per ontology category and per pathology

                                                      Proteins (n)                        Percentage of proteins                         
  --------------------------------------------------- ----------------------------------- ------------------------ ---------- ---------- -----
                                                      Total number of accession numbers   5848                     3654                  
  Total number of unique proteins                     3190                                2374                                           
  Molecular function                                  Antioxidant activity                14                       13         0.4        0.5
  Binding                                             841                                 649                      **26.4**   **27.3**   
  Catalytic activity                                  1051                                809                      **32.9**   **34.1**   
  Channel regulator activity                          5                                   4                        0.2        0.2        
  Receptor activity                                   64                                  37                       2.0        1.6        
  Signal transducer activity                          21                                  15                       0.7        0.6        
  Structural molecule activity                        285                                 235                      8.9        9.9        
  Translation regulator activity                      26                                  21                       0.8        0.9        
  Transporter activity                                146                                 102                      4.6        4.3        
  Biological process                                  Biological adhesion                 77                       55         2.4        2.3
  Biological regulation                               232                                 165                      7.3        7.0        
  Cellular component organisation or biogenesis       414                                 339                      **13.0**   **14.3**   
  Cellular process                                    1338                                1023                     **41.9**   **43.1**   
  Developmental process                               217                                 162                      6.8        6.8        
  Growth                                              1                                   1                        0.0        0.0        
  Immune system process                               139                                 83                       4.4        3.5        
  Localisation                                        409                                 311                      **12.8**   **13.1**   
  Locomotion                                          19                                  16                       0.6        0.7        
  Metabolic process                                   1235                                943                      **38.7**   **39.7**   
  Multicellular organismal process                    193                                 140                      6.1        5.9        
  Reproduction                                        27                                  24                       0.8        1.0        
  Response to stimulus                                248                                 171                      7.8        7.2        
  Cell component                                      Cell junction                       20                       15         0.6        0.6
  Cell part                                           914                                 717                      **28.7**   **30.2**   
  Extracellular matrix                                31                                  21                       1.0        0.9        
  Extracellular region                                97                                  64                       3.0        2.7        
  Macromolecular complex                              359                                 286                      **11.3**   **12.0**   
  Membrane                                            207                                 152                      6.5        6.4        
  Organelle                                           566                                 446                      **17.7**   **18.8**   
  Synapse                                             8                                   5                        0.3        0.2        
  Protein class                                       Calcium-binding protein             85                       64         2.7        2.7
  Cell adhesion molecule                              52                                  38                       1.6        1.6        
  Cell junction protein                               21                                  18                       0.7        0.8        
  Chaperone                                           63                                  49                       2.0        2.1        
  Cytoskeletal protein                                210                                 167                      6.6        7.0        
  Defense/immunity protein                            40                                  31                       1.3        1.3        
  Enzyme modulator                                    268                                 200                      8.4        8.4        
  Extracellular matrix protein                        55                                  40                       1.7        1.7        
  Hydrolase                                           255                                 189                      8.0        8.0        
  Isomerase                                           54                                  42                       1.7        1.8        
  Ligase                                              79                                  56                       2.5        2.4        
  Lyase                                               43                                  38                       1.3        1.6        
  Membrane traffic protein                            93                                  69                       2.9        2.9        
  Nucleic acid binding                                412                                 323                      **12.9**   **13.6**   
  Oxidoreductase                                      198                                 165                      6.2        7.0        
  Receptor                                            86                                  54                       2.7        2.3        
  Signalling molecule                                 107                                 80                       3.4        3.4        
  Storage protein                                     1                                   1                        0.0        0.0        
  Structural protein                                  27                                  20                       0.8        0.8        
  Surfactant                                          1                                   1                        0.0        0.0        
  Transcription factor                                110                                 73                       3.4        3.1        
  Transfer/carrier protein                            83                                  64                       2.6        2.7        
  Transferase                                         227                                 171                      7.1        7.2        
  Transmembrane receptor regulatory/adaptor protein   13                                  10                       0.4        0.4        
  Transporter                                         123                                 81                       3.9        3.4        
  Viral protein                                       1                                   0                        0.0        0.0        

Proteins are also shown as a percentage of the number of unique proteins per pathology. The ontology categories with the 10 highest percentage of proteins per pathology are given in bold.

RV, right ventricle; TOF, tetralogy of Fallot; VSD, ventricular septal defect.

![Volcano plot of entire set of proteins quantified in the right ventricle of TOF versus VSD patients (positive log2 (fold change) indicates higher expression in TOF samples). Each point represents the difference in expression (log2 fold difference) between the groups, and the associated significance of this change (independent unpaired samples t-test). Proteins significantly altered (±1.3-fold, P\<0.05) are found within the grey shaded boxes. TOF, tetralogy of Fallot; VSD, ventricular septal defect.](openhrt-2017-000716f01){#F1}

###### 

Number of proteins in proteomics analysis, per ontology category, statistically compared between TOF and VSD RV samples

                                                                                          Proteins (n)   Percentage of total unique proteins (2357)                                                   
  --------------------------------------------------- ----------------------------------- -------------- -------------------------------------------- ----- ---------- ---------- --------- --------- -----
                                                      Total number of accession numbers   3610           3410                                         174   26                                        
  Total number of unique proteins                     **2357**                            2244           100                                          13    100        95.2       4.2       0.6       
  Molecular function                                  Antioxidant activity                13             13                                           0     0          0.6        0.6       0.0       0.0
  Binding                                             643                                 607            34                                           2     **27.3**   **25.8**   **1.4**   0.1       
  Catalytic activity                                  806                                 776            25                                           5     **34.2**   **32.9**   **1.1**   **0.2**   
  Channel regulator activity                          4                                   4              0                                            0     0.2        0.2        0.0       0.0       
  Receptor activity                                   36                                  32             4                                            0     1.5        1.4        0.2       0.0       
  Signal transducer activity                          14                                  13             0                                            1     0.6        0.6        0.0       0.0       
  Structural molecule activity                        234                                 217            15                                           2     9.9        9.2        0.6       0.1       
  Translation regulator activity                      21                                  20             1                                            0     0.9        0.8        0.0       0.0       
  Transporter activity                                101                                 95             5                                            1     4.3        4.0        0.2       0.0       
  Biological process                                  Biological adhesion                 54             53                                           1     0          2.3        2.2       0.0       0.0
  Biological regulation                               162                                 156            4                                            2     6.9        6.6        0.2       0.1       
  Cellular component organisation or biogenesis       335                                 319            12                                           4     14.2       13.5       0.5       **0.2**   
  Cellular process                                    1014                                965            42                                           7     **43.0**   **40.9**   **1.8**   **0.3**   
  Developmental process                               158                                 149            7                                            2     6.7        6.3        0.3       0.1       
  Growth                                              1                                   1              0                                            0     0.0        0.0        0.0       0.0       
  Immune system process                               81                                  75             6                                            0     3.4        3.2        0.3       0.0       
  Localisation                                        310                                 295            13                                           2     13.2       12.5       0.6       0.1       
  Locomotion                                          15                                  14             1                                            0     0.6        0.6        0.0       0.0       
  Metabolic process                                   939                                 900            34                                           5     **39.8**   **38.2**   **1.4**   **0.2**   
  Multicellular organismal process                    137                                 130            5                                            2     5.8        5.5        0.2       0.1       
  Reproduction                                        24                                  22             1                                            1     1.0        0.9        0.0       0.0       
  Response to stimulus                                169                                 158            9                                            2     7.2        6.7        0.4       0.1       
  Cell component                                      Cell junction                       14             1                                            0     0.6        0.6        0.0       0.0       
  Cell part                                           709                                 675            30                                           4     **30.1**   **28.6**   **1.3**   **0.2**   
  Extracellular matrix                                20                                  20             0                                            0     0.8        0.8        0.0       0.0       
  Extracellular region                                64                                  63             1                                            0     2.7        2.7        0.0       0.0       
  Macromolecular complex                              282                                 268            12                                           2     12.0       11.4       0.5       0.1       
  Membrane                                            149                                 144            5                                            0     6.3        6.1        0.2       0.0       
  Organelle                                           440                                 417            20                                           3     18.7       17.7       0.8       0.1       
  Synapse                                             5                                   5              0                                            0     0.2        0.2        0.0       0.0       
  Protein class                                       Calcium-binding protein             62             60                                           2     0          2.6        2.5       0.1       0.0
  Cell adhesion molecule                              38                                  35             3                                            0     1.6        1.5        0.1       0.0       
  Cell junction protein                               18                                  18             0                                            0     0.8        0.8        0.0       0.0       
  Chaperone                                           49                                  49             0                                            0     2.1        2.1        0.0       0.0       
  Cytoskeletal protein                                167                                 153            12                                           2     7.1        6.5        0.5       0.1       
  Defense/immunity protein                            31                                  29             2                                            0     1.3        1.2        0.1       0.0       
  Enzyme modulator                                    200                                 195            4                                            1     8.5        8.3        0.2       0.0       
  Extracellular matrix protein                        39                                  38             1                                            0     1.7        1.6        0.0       0.0       
  Hydrolase                                           189                                 180            9                                            0     8.0        7.6        0.4       0.0       
  Isomerase                                           41                                  39             2                                            0     1.7        1.7        0.1       0.0       
  Ligase                                              56                                  56             0                                            0     2.4        2.4        0.0       0.0       
  Lyase                                               38                                  36             2                                            0     1.6        1.5        0.1       0.0       
  Membrane traffic protein                            69                                  67             2                                            0     2.9        2.8        0.1       0.0       
  Nucleic acid binding                                320                                 306            12                                           2     13.6       13.0       0.5       0.1       
  Oxidoreductase                                      165                                 164            1                                            0     7.0        7.0        0.0       0.0       
  Receptor                                            52                                  48             4                                            0     2.2        2.0        0.2       0.0       
  Signalling molecule                                 79                                  76             3                                            0     3.4        3.2        0.1       0.0       
  Storage protein                                     1                                   1              0                                            0     0.0        0.0        0.0       0.0       
  Structural protein                                  20                                  17             1                                            2     0.8        0.7        0.0       0.1       
  Surfactant                                          1                                   1              0                                            0     0.0        0.0        0.0       0.0       
  Transcription factor                                72                                  67             5                                            0     3.1        2.8        0.2       0.0       
  Transfer/carrier protein                            64                                  61             3                                            0     2.7        2.6        0.1       0.0       
  Transferase                                         170                                 161            8                                            1     7.2        6.8        0.3       0.0       
  Transmembrane receptor regulatory/adaptor protein   10                                  10             0                                            0     0.4        0.4        0.0       0.0       
  Transporter                                         81                                  77             3                                            1     3.4        3.3        0.1       0.0       
  Viral protein                                       0                                   0              0                                            0     0.0        0.0        0.0       0.0       

The total number of proteins, and number significantly changed, or not, between pathologies are shown. Proteins are also shown as a percentage of the number of unique proteins. The ontology categories with the five highest percentage of proteins per pathology are given in bold.

RV, right ventricle; TOF, tetralogy of Fallot; VSD, ventricular septal defect.

Four hundred and fourteen phosphorylated proteins were also successfully identified, each containing at least one translation modification at serine, threonine or tyrosine (resulting in a total of 700 phosphorylation site matches). Of the phosphorylation sites identified, 117 significantly changed representing 97 unique proteins: 46 were lower in TOF and 71 were higher ([figure 2](#F2){ref-type="fig"}).

![Volcano plot of entire set of phosphorylated proteins quantified in the right ventricle of TOF versus VSD patients (positive log 2 (fold change) indicates higher expression in TOF samples). Each point represents the difference in expression (log 2 fold difference) between the groups, and the associated significance of this change (independent unpaired samples t-test). Proteins significantly altered (±1.3 fold, P\<0.05) are found within the grey shaded boxes. TOF, tetralogy of Fallot; VSD, ventricular septal defect.](openhrt-2017-000716f02){#F2}

Gene ontology enrichment analysis showed that cellular component proteins associated with the muscle/contractile fibre part (11 proteins) and specifically the Z-disc (eight proteins) were significantly enriched in those proteins that were higher in patients with TOF. For individual proteins associated with Gene Ontology (GO) terms, see [table 5](#T5){ref-type="table"}. Proteins and associated gene names are displayed in [table 6](#T6){ref-type="table"}. Molecular function proteins associated with α-catenin, calmodulin and cytoskeletal actin binding (3, 7 and 14 proteins, respectively) were enriched, as well as biological processes predominantly associated with heart and muscle contractility and regulation ([figure 3](#F3){ref-type="fig"}). There was no enrichment of proteins higher in VSD patients. Phosphorylated proteins associated with the biological processes actomyosin structure organisation, regulation of calcium-mediated signalling and regulation of calcium ion transmembrane transporter activity (5, 3 and 3 phosphoproteins, respectively), and the cellular components somatodendritic compartment, Z-disc and actomyosin (2, 4 and 5 phosphoproteins, respectively) were significantly enriched.

![Hierarchy of enriched gene ontology biological processes for expression of proteins that are higher in patients with TOF compared with VSD. Highlighted terms correspond to [table 5](#T5){ref-type="table"}. Figure exported from GOrilla analysis. TOF, tetralogy of Fallot; VSD, ventricular septal defect.](openhrt-2017-000716f03){#F3}

###### 

Enriched gene ontology terms for significantly higher total and phosphorylated protein levels in the right ventricle of patients with tetralogy of Fallot compared with ventricular septal defect

  Ontology             Protein type                                                                              GO term                                                                                            Description              P value                                                                                                                                                                       Proteins (n)                             Protein symbol
  -------------------- ----------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- ------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------- ------------------------------------------------------------------------
  Cellular component   Total                                                                                     GO:0044449                                                                                         Contractile fibre part   4E-05                                                                                                                                                                         11                                       CFL2, CMYA5, CSRP3, FHOD3, FLNC, MYOM1, MYOZ2, NEBL, OBSCN, RYR2, SVIL
  GO:0030018           Z-disc                                                                                    9E-05                                                                                              8                        CFL2, CSRP3, FHOD3, FLNC, MYOZ2, NEBL, OBSCN, RYR2                                                                                                                                                                     
  Phosphorylated       GO:0042641                                                                                Actomyosin                                                                                         6E-05                    4                                                                                                                                                                             CDC42BPB, MYO18A, NEBL, SORBS1           
  GO:0036477           Somatodendritic compartment                                                               1E-04                                                                                              2                        MAPT, STX4                                                                                                                                                                                                             
  GO:0044449           Contractile fibre part                                                                    7E-04                                                                                              5                        AHNAK, BAG3, JPH2, NEBL, OBSCN                                                                                                                                                                                         
  GO:0030018           Z-disc                                                                                    8E-04                                                                                              4                        BAG3, JPH2, NEBL, OBSCN                                                                                                                                                                                                
  Molecular function   Total                                                                                     GO:0045294                                                                                         Alpha-catenin binding    1E-05                                                                                                                                                                         3                                        AJUBA, CDH2, PKP2
  GO:0003779           Actin binding                                                                             4E-05                                                                                              14                       AJUBA, CFL2, CSRP3, FHOD3, FLII, FLNC, LIMCH1, MYOZ2, NEBL, SNTA1, SNTB2, SORBS1, SVIL, TWF2                                                                                                                           
  GO:0005516           Calmodulin binding                                                                        9E-04                                                                                              7                        CAMK2D, OBSCN, PPP3CC, RYR2, SNTA1, SNTB2, STRN                                                                                                                                                                        
  Biological process   GO:0010881                                                                                Regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion   3E-05                    4                                                                                                                                                                             CAMK2D, GSTM2, PLN, RYR2                 
  GO:0031032           Actomyosin structure organisation                                                         9E-05                                                                                              7                        CFL2, CSRP3, FHOD3, LIMCH1, MYOZ2, OBSCN, SORBS1                                                                                                                                                                       
  GO:0010882           Regulation of cardiac muscle contraction by calcium ion signalling                        9E-05                                                                                              4                        CAMK2D, GSTM2, PLN, RYR2                                                                                                                                                                                               
  GO:0014706           Striated muscle tissue development                                                        1E-04                                                                                              6                        CFL2, CSRP3, MYOM1, PLN, SEMA3C, SVIL,                                                                                                                                                                                 
  GO:1903522           Regulation of blood circulation                                                           1E-04                                                                                              9                        ADCY6, CAMK2D, CSRP3, GSTM2, PKP2, PLN, RYR2, SNTA1, TMEM65                                                                                                                                                            
  GO:0060537           Muscle tissue development                                                                 1E-04                                                                                              6                        CFL2, CSRP3, MYOM1, PLN, SEMA3C, SVIL                                                                                                                                                                                  
  GO:0010880           Regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum   2E-04                                                                                              4                        CAMK2D, GSTM2, PLN, RYR2                                                                                                                                                                                               
  GO:0008016           Regulation of heart contraction                                                           2E-04                                                                                              8                        CAMK2D, CSRP3, GSTM2, PKP2, PLN, RYR2, SNTA1, TMEM65                                                                                                                                                                   
  GO:0007010           Cytoskeleton organisation                                                                 3E-04                                                                                              16                       AJUBA, CFL2, CSRP3, ERBB2IP, FHOD3, FLII, LIMCH1, MYOZ2, NTMT1, OBSCN, PKP2, PRKCDBP, SHANK1, SORBS1, SVIL, TUBA4A                                                                                                     
  GO:0055119           Relaxation of cardiac muscle                                                              4E-04                                                                                              3                        CAMK2D, GSTM2, PLN                                                                                                                                                                                                     
  GO:0086005           Ventricular cardiac muscle cell action potential                                          4E-04                                                                                              3                        PKP2, RYR2, SNTA1                                                                                                                                                                                                      
  GO:0055117           Regulation of cardiac muscle contraction                                                  4E-04                                                                                              5                        CAMK2D, GSTM2, PKP2, PLN, RYR2                                                                                                                                                                                         
  GO:0002026           Regulation of the force of heart contraction                                              4E-04                                                                                              4                        CAMK2D, CSRP3, PLN, RYR2                                                                                                                                                                                               
  GO:1901077           Regulation of relaxation of muscle                                                        6E-04                                                                                              2                        CAMK2D, PLN                                                                                                                                                                                                            
  GO:1901897           Regulation of relaxation of cardiac muscle                                                6E-04                                                                                              2                        CAMK2D, PLN                                                                                                                                                                                                            
  GO:0002027           Regulation of heart rate                                                                  8E-04                                                                                              5                        CAMK2D, PKP2, PLN, RYR2, SNTA1                                                                                                                                                                                         
  GO:0006942           Regulation of striated muscle contraction                                                 1E-03                                                                                              5                        CAMK2D, GSTM2, PKP2, PLN, RYR2                                                                                                                                                                                         
  GO:0090075           Relaxation of muscle                                                                      1E-03                                                                                              3                        CAMK2D, GSTM2, PLN                                                                                                                                                                                                     
  Phosphorylated       GO:0031032                                                                                Actomyosin structure organisation                                                                  1E-05                    5                                                                                                                                                                             CDC42BPB, MYLK3, MYO18A, OBSCN, SORBS1   
  GO:0050789           Regulation of biological process                                                          3E-04                                                                                              25                       AHNAK, BAG3, BVES, CDC42BPB, JPH2, KANK2, KPNA4, LRRFIP2, MAPT, MYLK3, MYO18A, NUCKS1, OBSCN, OSBP, PLCL1, PLN, PSIP1, RBM20, RSF1, SCN7A, SGTA, SORBS1, SPEG, STX4, ZBTB7A                                            
  GO:0050848           Regulation of calcium-mediated signalling                                                 4E-04                                                                                              3                        JPH2, MAPT, PLN                                                                                                                                                                                                        
  GO:1901019           Regulation of calcium ion transmembrane transporter activity                              4E-04                                                                                              3                        AHNAK, JPH2, PLN                                                                                                                                                                                                       

###### 

List of proteins and associated gene name abbreviations

  Gene symbol   Protein name
  ------------- ----------------------------------------------------------------------------------------------------------------
  ADCY6         Adenylate cyclase type 6
  AHNAK         Neuroblast differentiation-associated protein AHNAK
  AJUBA         LIM domain-containing protein ajuba
  BAG3          BAG family molecular chaperone regulator 3
  BCAT2         Branched-chain-amino-acid aminotransferase, mitochondrial
  BCKDHA        2-Oxoisovalerate dehydrogenase subunit alpha, mitochondrial
  BCKDK         (3-methyl-2-oxobutanoate dehydrogenase (lipoamide)) kinase, mitochondrial
  BVES          Blood vessel epicardial substance
  C6orf57       Chromosome six open reading frame 57
  CAMK2D        Calcium/calmodulin-dependent protein kinase type II subunit delta
  CDC42BPB      Serine/threonine-protein kinase MRCK beta
  CDH2          Cadherin-2
  CFL2          Cofilin-2
  CMYA5         Cardiomyopathy-associated protein 5
  COA5          Cytochrome c oxidase assembly factor 5
  COBL          Protein cordon-bleu
  COL6A5        Collagen alpha-5(VI) chain
  COX1          Cytochrome c oxidase subunit 1
  CPT2          Carnitine O-palmitoyltransferase 2, mitochondrial
  CSRP3         Cysteine and glycine-rich protein 3
  DMD           Dystrophin
  ERBB2IP       Protein LAP2
  FDX1          Adrenodoxin, mitochondrial
  FHOD3         FH1/FH2 domain-containing protein 3
  FLII          Protein flightless-1 homolog
  FLNC          Filamin-C
  GSTM2         Glutathione S-transferase Mu 2
  HNRNPD        Heterogeneous nuclear ribonucleoprotein D0
  HRC           Sarcoplasmic reticulum histidine-rich calcium-binding protein
  JPH2          Junctophilin-2
  KANK2         KN motif and ankyrin repeat domain-containing protein 2
  KPNA4         Importin subunit alpha-3
  KRT10         Keratin, type I cytoskeletal 10
  KRT14         Keratin, type I cytoskeletal 14
  LCN2          Neutrophil gelatinase-associated lipocalin
  LDB3          LIM domain binding 3 isoform 1
  LIMCH1        LIM and calponin homology domains-containing protein 1
  LRRFIP2       Leucine-rich repeat flightless-interacting protein 2
  MAPT          Microtubule-associated protein
  MRPL12        39S Ribosomal protein L12, mitochondrial
  MYLK3         Myosin light chain kinase 3
  MYO18A        Unconventional myosin-XVIIIa
  MYOM1         Myomesin-1
  MYOM2         Myomesin (M-protein) 2, 165 kDa, isoform CRA_c
  MYOZ2         Myozenin-2
  ND1           NADH-ubiquinone oxidoreductase chain 1
  NEBL          Nebulette
  NTMT1         N-terminal Xaa-Pro-Lys N-methyltransferase 1
  NUCKS1        Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1
  OBSCN         Obscurin
  OGDH          2-Oxoglutarate dehydrogenase, mitochondrial
  OSBP          Oxysterol-binding protein 1
  PKP2          Plakophilin-2
  PLCL1         Inactive phospholipase C-like protein 1
  PLN           Cardiac phospholamban
  PPM1K         Protein phosphatase 1K, mitochondrial
  PPP3CC        Serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform
  PRKAR2A       Protein kinase cAMP-dependent regulatory type II alpha isoform 1
  PRKCDBP       Protein kinase C delta-binding protein
  PSIP1         PC4 and SFRS1-interacting protein
  RBM20         RNA-binding protein 20
  RSF1          Remodelling and spacing factor 1
  RYR2          Ryanodine receptor 2
  SCN7A         Sodium channel protein type 7 subunit alpha
  SDHD          Succinate dehydrogenase (ubiquinone) cytochrome b small subunit, mitochondrial
  SDHAF1        Succinate dehydrogenase assembly factor 1, mitochondrial
  SEMA3C        Semaphorin-3C
  SGTA          Small glutamine-rich tetratricopeptide repeat-containing protein alpha (Alpha-SGT) (Vpu-binding protein) (UBP)
  SHANK1        SH3 and multiple ankyrin repeat domains protein 1
  SNTA1         Alpha-1-syntrophin
  SNTB2         Beta-2-syntrophin
  SORBS1        Sorbin and SH3 domain-containing protein 1
  SPEG          Striated muscle preferentially expressed protein kinase
  SRL           Sarcalumenin
  STRN          Striatin
  STX4          Syntaxin-4
  SVIL          Supervillin
  SYNPO2L       Synaptopodin 2-like, isoform CRA_a
  TIMM22        Mitochondrial import inner membrane translocase subunit Tim22
  TMEM65        Transmembrane protein 65
  TNNI3         Mutant cardiac troponin I
  TPM1          Tropomyosin 1 (Alpha), isoform CRA_a
  TSFM          Elongation factor Ts, mitochondrial
  TUBA4A        Tubulin alpha-4A chain
  TUBB4A        Tubulin beta-4A chain
  TWF2          Twinfilin-2
  XIRP1         Xin actin-binding repeat-containing protein 1
  ZBTB7A        Zinc finger and BTB domain-containing protein 7A

Structural and extracellular matrix protein and calcium signalling comparisons {#s2c}
------------------------------------------------------------------------------

Structural proteins in human skeletal muscle were cross-referenced against protein lists found in our different samples. One hundred and nine accession numbers (representing 97 proteins) were detected, and 12 (12.4%) of these were significantly higher in TOF. Six of these were associated with sarcomeric function that included Z-disc proteins (muscle LIM protein (CSRP3), filamin-C, ZASP), M-band and giant muscle proteins (myomesin-1 and obscurin) and the thin filament protein, tropomyosin-1. The remaining six proteins were associated with actin-binding (supervillin, cardiomyopathy-associated protein 5, synaptopodin 2-like protein and cordon-bleu protein), calcium signalling (phospholamban) and myocyte cytoskeletal development (striated muscle preferentially expressed protein kinase; by similarity with members of myosin light chain kinase family). Additionally, adenylate cyclase six was higher in TOF samples. Phosphopeptide enrichment led to higher levels of 9 proteins in TOF samples compared with VSD, some with multiple phosphorylation sites. These were calcium signalling proteins (neuroblast differentiation-associated protein AHNAK--Ser4425 and AHNA K--Ser5110, sarcoplasmic reticulum histidine-rich calcium-binding protein --Ser145 and --Ser457, junctophilin-2 --Threonine (Thr)490, phospholamban-Ser16 and phospholamban-Ser16/Thr17), Z-disk proteins (obscurin-Ser5563 and dystrophin-Ser432), BAG family molecular chaperone regulator 3-Ser289 (which stimulates expression of cytoskeleton), striated muscle preferentially expressed protein kinase-Ser2448 and protein kinase-Ser2014/Ser2015, and nuclear ubiquitous casein and cyclin-dependent kinase substrate-Ser113 (highly expressed in cardiac tissue, but with unknown function). Six phosphoproteins had lower levels in TOF samples: AHNAK-Ser1068 and AHNAK-Ser5369 (calcium signalling), myomesin-1-Ser36 and myomesin-2-Ser39, myomesin-2-Ser76, myomesin-2-Ser78, myomesin-2-Ser1461 (M-band proteins), Xin actin-binding repeat-containing protein 1-Ser208 (actin-binding) and protein kinase cAMP-dependent regulatory type II alpha-Ser78 (protein kinase activity).

Of the list of extracellular matrix proteins searched, four were higher in VSD (collagen VI, keratin-10 and keratin-14 and tubulin-β4 A), and five were higher in TOF samples (cofilin-2, cadherin-2, myomesin-1, tropomyosin-1 and tubulin-α4 A). Additionally, three phosphorylated proteins were lower in TOF samples: myomesin 1-Ser36 (also in structural proteins list), myomesin 2 at phosphosites-Ser39, phosphosites-Ser76 and phosphosites-Ser1461 and troponin I at Ser199.

Clinical outcome data {#s2d}
---------------------

All children survived without any major complications. However, as expected there were significant differences in outcome data ([table 7](#T7){ref-type="table"}). The number of days of mechanical ventilation, the pressure in the superior vena cava at 4 hours, the peak rate of dopamine, the length of time of required dopamine infusion, the peak rate of milrinone, the length of time of milrinone requirement and the number of days of pleural drains in situ were all not significantly different in the two groups. One child with TOF had longer time in intensive care, longer time on milrinone, longer hospital stay and longer time in oxygen than the others. As a result, there was a mildly significant difference in the length of time that supplemental oxygen was required between the VSD group and the TOF group. However, this all resolved by discharge. Two children had arrhythmias in the VSD group and one with supraventricular tachycardia and with complete heart block but both resolved by the time of leaving the intensive care. Three children with TOF had junctional ectopic tachycardia but resolved with standard approach of cooling and short-term amiodarone usage. None required long-term medication. All children were discharged home on furosemide and spironolactone. Two children with VSD repair were discharged home on captopril. One child with TOF required captopril at discharge and one child had propranolol for stiff RV.

###### 

Clinical outcome data

                                            Group 1 VSD n=6   Group 2 TOF n=6   P value
  ----------------------------------------- ----------------- ----------------- ---------
  Ventilation time (median days)            0.833             5.2               ns
  SVC pressure (median mm Hg)               11.2              10.7              ns
  Dopamine (median peak rate, µg/kg/min)    4.2               7.5               ns
  Dopamine (median hours)                   12.5              59                ns
  Milrinone (median peak rate, µg/kg/min)   0.5               0.57              ns
  Milrinone (median hours)                  39.7              88                ns
  Pleural drains (median days)              2.3               2.3               ns
  Arrhythmias (number of children)          2                 3                 ns
  Oxygen duration (median, days)            2                 5.1               0.043
  Intensive care stay (median, days)        2.7               4.5               ns
  Hospital stay (median days)               6.5               9.5               ns

SVC, superior vena cava; TOF, tetralogy of Fallot; VSD, ventricular septal defect.

Discussion {#s3}
==========

The present study is the first to attempt to correlate changes in myocardial proteins with clinical and echocardiographic data in order to try to understand the adaptive, maladaptive and remodelling pathways in the two groups of patients with hypertensive RVs. These two groups were chosen since they both have RVs that were functioning at systemic pressure. Both groups of infants were of the same age at the time of operation, and there was the same sex distribution. Hence, confounders relating to these diseases have been removed. The only difference between the two groups was the physiology---one being volume loaded and the other being after loaded---in addition to the systemic oxygen saturation being significantly lower in the group with TOF.

We confirmed previous studies that have shown the RV to be stiff in those children who have TOF,[@R5] and our gene ontology protein enrichment data lends further support to this, with proteins found to be higher in patients with TOF in the contractile part of the cell and in particular the Z-disc. Enrichment of differentially expressed proteins within processes regulating heart and muscle contractility also support this.

The contractile units of myocytes are the sarcomeres, and within these, the thin actin filaments and thick myosin filaments generate the contractile force. Many other proteins surround and support these to make up the sarcomeric scaffold, which affects the efficiency and transmission of the generated force.[@R6] In our patients, there were no significant differences in expression between actin or myosin; however in the RV of hearts with high after load, as in TOF, there were increases in the amounts of supporting proteins, for example, muscle LIM protein, filamin-C, obscurin, myomesin-1 and ZASP, which have roles in cross-linking and connecting filaments, Z-disc assembly, mechano-sensing and myocyte signalling.[@R7] The evidence that MYOM1 is present in the myocardium of neonatal dogs might have relevance to our patients, if we later found it to be reduced in amount in older children with the same condition.[@R12] It is possible that overexpression of these proteins is linked with decreased ability to relax and that there is failure of the RV to develop past the phenotype seen in the neonate. Further studies would be needed to determine whether this disappears in older children with TOF once repair had been performed. The giant protein titin stretches between the Z-disc and M-line of the sarcomere and is thought to be a key player in passive myocardial stiffness and contraction.[@R14] Our data showed a non-significant increase (1.4-fold) in titin content of TOF samples; further interrogation showed no significant correlation between titin expression and E/A wave ratio as a stiffness indicator. However, previous work has shown that it may be the ratio of cardiac titin isoforms that is important in heart failure and stiffness (which was not looked at here) and not total expression.[@R15] We have shown that in the hearts of infants with TOF, which have evidence of increased stiffness and pressure afterload, there is an increase in some of the contractile proteins. It should however be noted that in this study, due to unavailability of healthy patient control tissue, we cannot definitively say that proteins are abnormally altered in either pathology, only that there are differences between the pathologies. It is unclear whether the predominantly enhanced expression of proteins in TOF is due to right ventricular remodelling of the myocytes and the onset of hypertrophy or a compensatory mechanism. Studies on aortas from rats with type 2 diabetes have shown that increased ROS caused by oxidative stress upregulates contractile protein expression resulting in vascular wall remodelling.[@R16]

Perhaps of greater importance is the differences in phosphorylation of proteins involved in the ventricle contractile processes. Phosphorylation of proteins indicates a change in protein function (either activation or deactivation) and enrichment was seen in proteins at various phosphorylation sites with higher levels in TOF, associated with calcium signalling and contractility pathways. Of the phosphorylation sites we detected in our proteomics analysis, many of them have not been detected previously in heart tissue (PhosphositePlus, accessed March 2017[@R17]), the exceptions being the following (R denotes regulatory protein, and K denotes associated kinases where known): phospholamban-ser16 (R: protein phosphatase 1 regulatory inhibitor subunit 1A,[@R18] K: cAMP-dependent protein kinase catalytic subunit alpha[@R19]) and -thr17 (R: tumour necrosis factor-α receptor subtypes 1 and 2,[@R20] K: cAMP-dependent protein kinase catalytic subunit alpha[@R19]), myomesin 2-ser76 (K: cAMP-dependent protein kinase catalytic subunit alpha,[@R21] protein kinase cAMP-dependent regulatory type II-α-ser78 and cardiac troponin I-ser199) (K: cAMP-dependent protein kinase catalytic subunit alpha).[@R22] The interaction of cardiac troponin I-Ser199 with its putative kinase has been shown to be inhibited by tropomyosin I,[@R23] which was significantly higher in TOF samples, resulting in altered force of contraction.

Previous studies have shown some changes in calcium signalling in congenital heart disease, but it has not been possible to determine whether this is a generic response to RV hypertension or to specific cardiac physiologies.[@R24] Proteins associated with calcium signalling were detected with adenylate cyclase 6, calcium/calmodulin-dependent protein kinase, phospholamban, ryanodine receptor 2 and sarcalumenin all being significantly higher in TOF. Phosphosites for phospholamban at Ser16, sarcoplasmic reticulum histidine-rich calcium-binding protein at Ser145 and junctophilin-2 at Thr490 were higher in TOF. However, cardiac troponin I at Ser199 was lower. The finding for phospholamban-Ser16 is similar to our previous studies and was linked to hypoxaemia.[@R25]

Although children with TOF clearly are more cyanosed, it is not clear how this would affect the RV. The biopsies are taken from the cavity of the RV that would normally see the venous (desaturated) blood. Systemic desaturation would not be expected to affect the endocardial surface of the RV.[@R27] It should be noted that hypoxia-inducible factor-1-alpha (HIF-1α) was not detected in our proteomics analysis, despite oxygen saturation levels indicating hypoxia, especially in the TOF patients. It would be expected that HIF-1α be present in all our samples as has previously been described for CHD,[@R29] suggesting the abundance was too low to detect with our protocol. However, we know that the RV is stiff after definitive cardiac surgery for TOF, which might relate to abnormalities of contractile proteins, secondary to an obstructed RV in comparison with the volume loaded RV of children with large post-tricuspid left to right shunt (VSD).[@R30] For the first time, we have made a direct comparison between the hypertensive RV of children with VSD and the RV of children with TOF.

The novel findings for the rest of the proteins/phosphoproteins provide further evidence for maladaptation of the RV in cyanotic TOF patients with implications for increased stiffness after open-heart surgery. The lack of functional measurements, for instance, single permeabilised cardiomyocyte measurements to assess systolic and diastolic properties, calcium sensitivity and cross-bridge kinetics, make it difficult to understand the functional relevance of the observed differences in cellular signalling between the two patient groups. It would be helpful to understand this in future studies, but the amount of tissue available from such small children limits the possibility under the current approvals for this study. A large piece of RV tissue would be required, and there is some doubt that the digestion process required to achieve single cells might render the sample unrepresentative.

Comparison with known cardiac disease {#s3a}
-------------------------------------

Genes known to be affected in myocardial disorders with ventricular dysfunction (hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM) and arrhythmogenic right ventricular cardiomyopathy (ARVC) (KEGG (Kyoto Encyclopaedia of Genes and Genomes) pathways map0510, map0514 and map05412 respectively[@R31]) were compared with our proteomics data. The majority of the affected proteins in these diseases were also present in our samples (11/15 HCM, 9/13 DCM, 5/6 ARVC); however, only tropomyosin-1 (normally affected in HCM and DCM, but not ARVC) was significantly higher in TOF samples. This suggests there was no downregulation of contractility as seen in maladaptation and right ventricular cardiomyopathy but more likely the upregulation due to increased myocardial wall stress.[@R32]

Conclusion {#s4}
==========

For the first time, it is now possible to suggest a cellular mechanism for the stiff RV in TOF, in that we have shown abnormalities in the calcium signalling pathways of the right ventricular myocardium. We have shown increased expression of myocardial contractile and extracellular proteins in TOF as compared with VSD, showing an adaptive physiology that is unrelated to age. We have shown that there is also parallel abnormality of clinical, echocardiographic and outcome data that might allow us, in future, to customise the treatment of the individual child in relation to their post-translational proteomics. It is too early to relate one finding directly to the other, but further work needs to be performed to determine the relationship between these important changes in RV hypertension in congenital heart disease.

**Contributors:** RMT, M-SG, SJG and MG designed the study and protocol. MC collected RV samples. CG performed and analysed the clinical and echocardiographic data. ARB, DI, SA-G and KH performed the laboratory analysis. RMT and AJB wrote the first draft, and all authors provided input to and approved the final version of the manuscript.

**Funding:** Sparks, the Childrens charity \* 13BTL01. This study was supported by the NIHR Biomedical Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol. University Hospitals Bristol NHS Foundation Trust department of research and innovation number CH/2014/4571 provided sponsorship.

**Disclaimer:** The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

**Competing interests:** None declared.

**Patient consent:** Detail has been removed from this case description/these case descriptions to ensure anonymity. The editors and reviewers have seen the detailed information available and are satisfied that the information backs up the case the authors are making.

**Ethics approval:** Ethical approval was granted by the National Research Ethics Service number 14/NW/1256, IRAS 143683.

**Provenance and peer review:** Not commissioned; internally peer reviewed.
